Abstract:Abstract Introduction The complex spatial cellular interactions of immune cell populations within the melanoma TIME are associated with patient prognosis and immunotherapy response. Novel multiplex immunofluorescence (mIHC) and spatial analysis techniques enable comprehensive investigation of these interactions. This study aimed to develop an automated spatial analysis workflow for large patient cohorts and to determine immunospatial patterns associated with outcome in patients (pts) with primary melanoma as well as pts with stage III melanoma treated with adjuvant immunotherapy. Methods Two cohorts with available clinical & mIHC data were studied: one of primary melanoma pts (primary cohort, n=46), and another of baseline resected stage III melanoma pts who received adjuvant anti-PD-1 (stage III cohort, n=119). Melanoma tissue was stained for CD8+ T cells and the markers CD103, PD-1 and CD39 in both cohorts and the primary cohort was additionally stained for NK cells, B cells, and Langerhans cells (LCs). mIHC data was investigated using the SPIAT spatial analysis R package. Immune-melanoma and immune-immune spatial relationships were quantified throughout the entire tissue and analysed using neighborhood analysis and cell colocalization metrics including entropy and mixing interaction scores. Results In the primary melanoma cohort, 11 neighborhood metaclusters (NMCs) were identified from 1617 neighborhoods. NMCs with high B cells, CD39+CD103+ CD8+ T cells, or LCs were associated with improved outcomes in this cohort. Neighborhood composition varied significantly based on tissue localisation, with B cells, LCs and NK cells significantly increased in marginal and stromal neighborhoods (p<0.0001). Over 100 B cell aggregate (BCA) neighborhoods were identified predominantly at the tumor margins and adjacent stroma. These BCAs were likely early TLSs based on their localisation and immune composition. BCA composition was further compared based on patient outcomes, with those harboring increased CD103-PD-1+ CD8+ T cells associated with poor outcome. In-depth pairwise analysis of immune phenotypes with melanoma cells found that increased B cell-melanoma and CD103+PD-1- CD8+ T cell-melanoma interaction was associated with improved outcomes in the primary cohort. In the stage III cohort, increased intratumoral immune diversity was associated with reduced melanoma recurrence (p=0.0004). Conclusions In developing a cohort-wide TIME spatial analytic approach and workflow, we identified multiple immunospatial associations with patient outcome in primary and stage III metastatic melanoma. Intratumoral immune diversity and immune cell neighborhoods indicate beneficial anti-tumor immune functions contributing towards improved patient outcomes. Citation Format: Grace Heloise Attrill, Eva R. Shteinman, Xinyu Bai, Felix Marsh-Wakefield, Camelia Quek, Umaimainthan Palendira, Ismael A. Vergara, Georgina V. Long, Richard A. Scolyer, James S. Wilmott. Spatial organization of the tumour immune microenvironment (TIME) in primary and metastatic melanoma is associated with patient outcome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2369.

Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status

Immune organization in sentinel lymph nodes of melanoma patients is prognostic of distant metastases

Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

Complete lymph node dissection in cutaneous melanoma patients with positive sentinel lymph node: Outcome and predictors in a retrospective cohort study over 16 years

Implications of tumor-positive sentinel lymph nodes in single vs multiple nodal basins in melanoma

Abstract 5530: Metastasis founder cells activate immunsuppression early in human metastatic colonization

Abstract 1503: Melanoma-derived lymphatic extracellular vesicles suppress dendritic cell differentiation and maturation in the sentinel lymph node

Spatial Proximity and Relative Distribution of Tumor-Infiltrating Lymphocytes and Macrophages Predict Survival in Melanoma

Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary study

The Prognostic Significance of Non‐sentinel Lymph Node Metastasis in Cutaneous and Acral Melanoma Patients—a Multicenter Retrospective Study

Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: A retrospective study of surveillance, epidemiology, and end-result population-based data.

Abstract 2369: Spatial organization of the tumour immune microenvironment (TIME) in primary and metastatic melanoma is associated with patient outcome

Prognostic Impact of the Immune-Cell Infiltrate in N1-Positive Non-Small-Cell Lung Cancer

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node

Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary to in-transit and distant metastasis in acral melanoma.

Investigation of Prognostic Factors for Non-Sentinel Lymph Node Metastasis in Patients Undergoing Sentinel Lymph Node Biopsy for Cutaneous Malignant Melanoma: Experience from a Reference Center in Turkey

Abstract 3132: Highly expressed wnt10b is associated with immune repression status in recurrent melanoma patients with positive sentinel lymph nodes

Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours

Melanocytic nevi in sentinel lymph nodes: association with cutaneous nevi and clinical relevance in patients with cutaneous melanomas

Langerhans Cells in Sentinel Lymph Nodes from Melanoma Patients